Bristol Myers Squibb Co 8-K, filed Jul 25, 2025
Bristol Myers Squibb Co (BMY)
8-K
2025-07-25
For: 2025-07-21
View Original
Added on
April 02, 2026
About this 8-K
Bristol Myers Squibb Co filed this 8-K on July 25, 2025, reporting on events of July 21, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 21, 2025
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S Employer Identification No.)
|
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code): (609 ) 252-4621
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
(b) On July 25, 2025, Bristol-Myers Squibb Company (the “Company”) announced that Dr. Samit Hirawat, Chief Medical Officer and Head
of Development, will leave the Company by November 1, 2025. In connection with his departure, Dr. Hirawat will transition from his current role as Executive Vice President, Chief Medical Officer and Head of Development, effective August 1, 2025, to
become an advisor to the Company.
(e) In connection
with his departure, Dr. Hirawat will be entitled to (i) severance benefits in accordance with the Company’s U.S. Severance Benefits Plan, (ii) pro-rated vesting of Market Share Units (MSUs) and Performance Share Units (PSUs), in each case, in
accordance with the Company’s equity award agreements under the Company’s 2021 Stock Award and Incentive Plan, and (iii) a prorated annual incentive payout for 2025 in accordance with the Company’s Senior Executive Performance Incentive Plan.
A copy of the press release announcing the departure of Dr. Hirawat is attached to this report as Exhibit 99.1.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
The following exhibits are furnished as part of this Current Report on Form 8-K:
|
Exhibit
No.
|
Description
|
|
|
Press release of Bristol-Myers Squibb Company dated July 25, 2025.
|
||
|
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
|
BRISTOL-MYERS SQUIBB COMPANY
|
||
|
Dated: July 25, 2025
|
By:
|
/s/ Amy Fallone
|
|
Name:
|
Amy Fallone
|
|
|
Title:
|
Corporate Secretary
|
|
Exhibit 99.1
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team
Samit Hirawat, M.D., Executive Vice
President, to step down from his role on August 1 and will depart BMS on November 1
PRINCETON, N.J., [BUSINESS WIRE] – Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief
Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company’s early-stage and late-stage product development across all therapeutic areas.
“We are thrilled to welcome Cristian to Bristol Myers Squibb,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers
Squibb. “His deep scientific expertise, strong focus on clinical execution and proven track record of regulatory approvals will be instrumental as we continue to advance our pipeline and deliver breakthrough medicines to even more patients around the
world. Cristian also has a very strong track record of building and developing world-class teams.”
“I am on a mission to discover new medicines - unlocking innovative approaches to researching and treating challenging diseases so that one day, no patient will hear that
all options have been exhausted. I am excited to join BMS in this shared purpose, with its storied history, vast pipeline across therapeutic areas, exceptional reputation, and culture deeply committed to making a
difference,” said Dr. Massacesi.
Samit Hirawat, M.D., Bristol Myers Squibb’s Executive Vice President, Chief Medical Officer, and Head of Development for the past six years, is stepping down to pursue
new professional opportunities. Dr. Hirawat will transition from his current role, effective August 1, 2025, and will remain an advisor to the Company through November 1, 2025, to ensure a seamless transition.
Boerner continued, "We sincerely thank Samit for his leadership and dedication to innovative drug development at BMS over the past six years. Under his guidance, we have
advanced groundbreaking science that has culminated in the approval of many new products across oncology, hematology, immunology, cardiovascular, and neuroscience. His commitment and visionary approach have driven our progress and positioned us at
the forefront of impactful medical innovation."
About Cristian Massacesi, M.D.
Dr. Massacesi began his career in the healthcare field as a medical oncologist, bringing the ethos of putting patients first into his more than 20 years of global
biopharmaceutical experience. He has a proven track record of advancing breakthrough science from early through late-stage development and global regulatory approvals, inspiring and encouraging his teams to identify novel strategies and take smart
risks.
He most recently served as Chief Medical Officer of AstraZeneca and Alexion and as Oncology Chief Development Officer at AstraZeneca, where he led a global organization of
more than 3,000 employees. Under his leadership, AstraZeneca advanced over 150 clinical studies and secured multiple regulatory approvals. Prior to his tenure at AstraZeneca, Dr. Massacesi held senior R&D positions at Pfizer and Novartis, where
he oversaw development programs across solid tumors and hematologic malignancies.
Dr. Massacesi will be based in Princeton, New Jersey, and report directly to Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb.
About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and
deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.
###
corporatefinancial-news
Media Inquiries:
media@bms.com
Investors:
investor.relations@bms.com